Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: A randomised phase 3 trial
The Lancet Oncology,  Clinical Article

Coiffier B et al. – A regimen of bortezomib plus rituximab is feasible. The improvement in progression-free survival provided by this regimen versus rituximab alone was not as great as expected. The regimen might represent a useful addition to the armamentarium, particularly for some subgroups of patients.

Methods

  • Multicentre phase 3 trial, rituximab-naive or rituximab-sensitive patients aged 18 years or older with relapsed grade 1 or 2 follicular lymphoma were randomly assigned (1:1) to receive five 35-day cycles consisting of intravenous infusions of rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and on day 1 of cycles 2—5, either alone or with bortezomib 1·6 mg/m2, administered by intravenous injection on days 1, 8, 15, and 22 of all cycles

Results

  • Between April 10, 2006, and Aug 12, 2008, 676 patients were randomised to receive rituximab (n=340) or bortezomib plus rituximab (n=336)
  • After median follow-up of 33·9 months (IQR 26·4—39·7), median PFS 11·0 months (95% CI 9·1—12·0) in rituximab group and 12·8 months (11·5—15·0) in bortezomib plus rituximab group (HR 0·82, 95% CI 0·68—0·99; p=0·039)
  • Magnitude of clinical benefit not as large as anticipated prespecified improvement of 33% in PFS
  • Patients in both groups received median of 5 treatment cycles (range 1—5); 245 of 339 (72%) and 237 of 334 (71%) patients in rituximab and bortezomib plus rituximab groups completed 5 cycles
  • Of patients who did not complete 5 cycles, most discontinued early because of disease progression (77 [23%] patients in rituximab group, and 56 [17%] patients in bortezomib plus rituximab group)
  • Rates of AE of grade 3 or higher (70 [21%] of 339 rituximab-treated patients vs 152 [46%] of 334 bortezomib plus rituximab treated patients), and serious AE (37 [11%] patients vs 59 [18%] patients) lower in rituximab group than in combination group
  • Most common AE of grade 3 or higher were neutropenia (15 [4%] patients in rituximab group and 37 [11%] patients in bortezomib plus rituximab group), infection (15 [4%] patients and 36 [11%] patients, respectively), diarrhea (no patients and 25 [7%] patients), herpes zoster (one [<1%] patient and 12 [4%] patients), nausea or vomiting (two [<1%] patients and 10 [3%] patients, respectively) and thrombocytopenia (2 [<1%] patients and 10 [3%] patients)
  • No individual serious AE reported by more than 3 patients in rituximab group; in bortezomib plus rituximab group, only pneumonia (7 patients [2%]) and pyrexia (6 patients [2%]) reported in more than 5 patients
  • In bortezomib plus rituximab group 57 (17%) of 334 patients had peripheral neuropathy (including sensory, motor, and sensorimotor neuropathy), including 9 (3%) with grade 3 or higher, compared with three (1%) of 339 patients in rituximab group (no events of grade ?3)
  • No patients in rituximab group but 3 (1%) patients in bortezomib plus rituximab group died of AE considered at least possibly related to treatment

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer European Journal of Cancer, August 6, 2014    Clinical Article

2 Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: The Cancer-DACUS Study Journal of Clinical Oncology, October 10, 2014    Clinical Article

3 Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09) Full Text European Urology, August 15, 2014    Free full text    Clinical Article

4 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 23, 2014    Clinical Article

5 Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial The Lancet Oncology, October 3, 2014    Clinical Article

6 Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial The Lancet Oncology, October 7, 2014    Clinical Article

7 Pathologic findings at risk-reducing salpingo-oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199 Journal of Clinical Oncology, September 22, 2014    Clinical Article

8 Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial The Lancet Oncology, October 20, 2014    Clinical Article

9 Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor Medical Oncology, September 22, 2014    Clinical Article

10 Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer International Journal of Cancer, September 29, 2014    Clinical Article

11 Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data The Lancet Oncology, September 24, 2014    Clinical Article

12 Lung cancer probability in patients with CT-detected pulmonary nodules: A prespecified analysis of data from the NELSON trial of low-dose CT screening The Lancet Oncology, October 9, 2014    Clinical Article

13 Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial The Lancet Oncology, September 25, 2014    Clinical Article

14 Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial The Lancet Oncology, October 8, 2014    Clinical Article

15 Salt tea consumption and esophageal cancer, a possible role of alkaline beverages in esophageal carcinogenesis International Journal of Cancer, September 15, 2014    Clinical Article

16 Everolimus plus exemestane for hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Overall survival results from BOLERO-2 Annals of Oncology, September 30, 2014    Clinical Article

17 Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the Randomized SweDCIS Trial Journal of Clinical Oncology, October 17, 2014    Clinical Article

18 Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial The Lancet Oncology, October 30, 2014    Clinical Article

19 Screening for prostate cancer in the US? Reduce the harms and keep the benefit International Journal of Cancer, August 15, 2014    Clinical Article

20 Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial The Lancet Oncology, October 22, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore